Compare BIOA & RPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BIOA | RPC |
|---|---|---|
| Founded | 2015 | 1992 |
| Country | United States | United States |
| Employees | 64 | 267 |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 856.3M | 932.7M |
| IPO Year | N/A | N/A |
| Metric | BIOA | RPC |
|---|---|---|
| Price | $21.56 | $8.32 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $40.50 | $12.00 |
| AVG Volume (30 Days) | 601.6K | ★ 911.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 1.87% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $53.06 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.88 | $8.02 |
| 52 Week High | $24.00 | $9.32 |
| Indicator | BIOA | RPC |
|---|---|---|
| Relative Strength Index (RSI) | 67.70 | 46.45 |
| Support Level | $18.62 | N/A |
| Resistance Level | $24.00 | N/A |
| Average True Range (ATR) | 1.43 | 0.52 |
| MACD | -0.06 | -0.03 |
| Stochastic Oscillator | 78.10 | 30.07 |
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.
Ridgepost Capital Inc, formelrly P10 Inc is a player in the alternative asset management sector, specializing in multi-asset class private market solutions. It offers a range of investment solutions, including specialized funds, separate accounts, secondary investments, direct investments, and co-investments across various asset classes and geographies. These solutions cater to diverse investor needs within the private markets, aiming to deliver superior risk-adjusted returns. With a focus on middle and lower-middle markets, the company's portfolio includes Private Equity, Venture Capital, Impact Investing, and Private Credit. Its Revenue primarily comes from recurring management and advisory fees earned on committed capital, typically locked up for ten to fifteen years.